Sanofi American Depositary Receipt (SNY)
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.
French govt set to take stake in Sanofi unit after PE sale
France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the business to US private equity firm Clayton, Dubilier & Rice (CD&R), despite political opposition. Sanofi entered exclusive talks with CD&R to sell 50% of Opella, the division behind well-known products like Doliprane, a popular painkiller in France.
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
France will take a stake in Sanofi 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is to take a 51% stake in the company that makes of one of France's most-sold painkillers, Doliprane.
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.
Workers at Sanofi to strike to protest consumer health unit sale, union official says
France's CGT and CFDT unions have called on workers at pharma company Sanofi to strike from Thursday to show their protest against a planned sale of a controlling stake in the firm's consumer health arm, a union official said on Wednesday.
France considering stake in Sanofi's Opella, minister says
France is considering taking a stake in Sanofi's Opella arm, said finance minister Antoine Armand, to allay concerns that the French drugmaker's plans to sell a 50% stake in Opella to a U.S. private equity firm could result in job cuts.
Should Value Investors Buy Sanofi (SNY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
French government seeking job guarantees from Sanofi over Doliprane production sites
The French government is seeking job guarantees from drugmaker Sanofi regarding its Doliprane production sites in the event of a sale of its consumer health branch, Economy Minister Antoine Armand said on Monday.
